Flunarizine in migraine: a double-blind placebo-controlled study (in a Saudi population).
We evaluated the effect of flunarizine (Fz) (10 mg/d) on migraine in a double-blind placebo-controlled design. The attacks' frequency, duration, severity and associated symptoms were compared before and after treatment. Forty-two patients completed a three-month trial period; 21 patients received Fz and 21 placebo. Statistical analysis showed no significant difference between Fz and placebo (p > 0.05). In this study Fz was not more efficient than placebo in migraine.
al Deeb
S M
SM
Department of Clinical Neurosciences, Riyadh Armed Forces Hospital, Kingdom of Saudi Arabia.
Biary
N
N
Bahou
Y
Y
al Jaberi
M
M
Khoja
W
W
D000293:Adolescent; D000328:Adult; D000368:Aged; D004311:Double-Blind Method; D005260:Female; D005444:Flunarizine / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D008881:Migraine Disorders / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D010919:Placebos; D013997:Time Factors
D010919:Placebos; D005444:Flunarizine